CAS: 1358715-18-0; 4-(4-Fluoro-3-(2-(Trifluoromethyl)-5,6,7,8-Tetrahydro-[1,2,4]Triazolo[1,5-A]Pyrazine-7-Carbonyl)Benzyl)Phthalazin-1(2H)-One

该化合物是一个复杂的有机化合物,其特点是具有独特的结构特征,包括一个phathalazinone核心和三氟甲基代三氟甲基三氮基三氮基-丙酰胺基.由于存在多个功能组,该化合物具有一系列化学特性特性,这些特性通常涉及先进的有机化学技术,其稳定性和与生物系统相互作用,因此,在决定其多种化学设计中具有重要的整体特征.

结构式图片

物理性质

MSDS等安全信息

合成工艺路线路线简述

  • 合成目标产物 Fluzoparib 主要起始原料 2-Fluoro-5-((4-Oxo-3,4-Dihydrophthalazin-1-yl)Methyl)Benzoic Acid And 2-(Trifluoromethyl)-5,6,7,8-Tetrahydro-[1,2,4]Triazolo[1,5-A]Pyrazine
  • (文献来源)合成步骤主要原料 2-Fluoro-5-((4-Oxo-3,4-Dihydrophthalazin-1-yl)Methyl)Benzoic Acid 和 2-(Trifluoromethyl)-5,6,7,8-Tetrahydro-[1,2,4]Triazolo[1,5-A]Pyrazine

海关参考信息

专利信息


专利号:WO-2023143427-A1
优先权日:2022-01-27
标题 :Crystal form of arv-110 and preparation method therefor and use thereof
发明人：SHENG XIAOXIA; SHENG XIAOHONG; CAO YAQING
权利人:HANGZHOU SOLIPHARMA CO LTD
摘要:The present application relates to the field of drug synthesis, in particular to a crystal form of ARV-110 and a preparation method therefor and a use thereof. The crystal form of the ARV-110 at least has one of the following improved characteristics: the stability is good, the hygroscopicity is low, the solubility is good, the melting point is high, stable storage can be achieved, crystal transformation of a drug in a development process and storage is avoided, the preparation method is simple and reliable, and great development values are achieved.

专利号:CN-108379591-B
优先权日:2018-04-03
标 题 :Synthesis of Immune Agonist Targeting Compounds and Their Applications

专利号:CN-118878526-A
优先权日:2024-07-26
标题:Olaparib derivative containing o-naphthoquinone structure, synthesis method thereof and application of Olaparib derivative in preparation of anti-triple-negative breast cancer drugs

其他信息查阅

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

⚠️全国化工行业净网倡议书
📋制造商识别码
📖 海关编码查询
📝MSDS生成器

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Li X, Yuan X, Wang Z, Li J, Liu Z, Wang Y, Wei L, Li Y, Wang X. Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells. Front Oncol. 2022 Feb 18;12:819714. doi: 10.3389/fonc.2022.819714.
2: Li N, Zhang Y, Wang J, Zhu J, Wang L, Wu X, Yao D, Wu Q, Liu J, Tang J, Yin R, Lou G, An R, Zhang G, Xia X, Li Q, Zhu Y, Zheng H, Yang X, Hu Y, Zhang X, Hao M, Huang Y, Lin Z, Wang D, Guo X, Yao S, Wan X, Zhou H, Yao L, Yang X, Cui H, Meng Y, Zhang S, Qu J, Zhang B, Zou J, Wu L. Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial. J Clin Oncol. 2022 Aug 1;40(22):2436-2446. doi: 10.1200/JCO.21.01511. Epub 2022 Apr 11. 102(10):2845-2855. doi: 10.1007/s00277-023-05359-3. Epub 2023 Jul 27. 110(3):1064-1075. doi: 10.1111/cas.13947. Epub 2019 Feb 19.
5: Luo J, Dai X, Hu H, Chen J, Zhao L, Yang C, Sun J, Zhang L, Wang Q, Xu S, Xu Y, Liu N, Ying G, Wang P. Fluzoparib increases radiation sensitivity of non- small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials. J Cancer Res Clin Oncol. 2020 Mar;146(3):721-737. doi: 10.1007/s00432-019-03097-6. Epub 2019 Nov 30. 81(10):1221-1226. doi: 10.1007/s40265-021-01541-x. Erratum in: Drugs. 2021 Jul 10;: Erratum in: Drugs. 2021 Sep;81(13):1597.

合成参考文献


摘要:Kleemann A., Kutscher B., Reichert D., Bossart M., Pharmaceutical Substances, Thieme [Online], Stuttgart, (2026).
摘要:Caron, S.; Lee, J.; Liu, Y.; Nguyen, T. N.; Piper, J. L.; Vicini, A. C., Science of Synthesis: Modern Strategies in Organofluorine Chemistry, (2025) 2.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知